oncofetal fibronectin

01/01/2012 - "Serum oncofetal fibronectin (onfFN) mRNA in differentiated thyroid carcinoma (DTC): large overlap between disease-free and metastatic patients."
02/01/2000 - "Expression of oncofetal fibronectin messenger ribonucleic acid in fibroblasts in the thyroid: a possible cause of false positive results in molecular-based diagnosis of thyroid carcinomas."
01/06/2012 - "Recent studies strongly suggest the use of oncofetal fibronectin (onfFN) mRNA in diagnostic follow-up and staging due to its very high specificity for thyroid cancers. "
01/06/2012 - "Blood presence of circulating oncofetal fibronectin mRNA, by RT-PCR, does not represent a useful specific marker for the management and follow-up of thyroid cancer patients."
03/01/1999 - "Measurement of the expression of oncofetal fibronectin mRNA in thyroid carcinomas by competitive reverse transcription-polymerase chain reaction."

03/01/1990 - "Distribution of oncofetal fibronectin in human mammary tumors: immunofluorescence study on histological sections."
01/01/2023 - "Increased expression of the pathological O-glycosylated form of oncofetal fibronectin in the multidrug resistance phenotype of cancer cells."
01/01/2023 - "In addition, strong correlations exist between increasing oncofetal fibronectin expression levels and tumor stage, lymph node activity, and histological grade at the time of diagnosis. "
01/01/2023 - "We determined that oncofetal fibronectin is significantly overexpressed in most cancer types relative to corresponding normal tissues. "
01/01/2013 - "coli of a bivalent human recombinant antibody (L19) toward the oncofetal fibronectin (B-FN), a pan-tumor target. "

08/01/2008 - "We found that expression of glycosylated oncofetal fibronectin was increased in the invasive phenotype of oral carcinoma cell lines. "
07/01/1998 - "Restricted expression of oncofetal fibronectin mRNA in thyroid papillary and anaplastic carcinoma: an in situ hybridization study."
09/01/2007 - "Expression of oncofetal fibronectin mRNA in thyroid anaplastic carcinoma."
12/01/2001 - "We proved that by ABRP detection of oncofetal fibronectin(onfFN) mRNA in FNABs, papillary and anaplastic carcinomas are accurately diagnosed preoperatively. "
06/01/2000 - "A preoperative molecular-based diagnostic technique for thyroid papillary and anaplastic carcinomas was recently developed to detect oncofetal fibronectin (onfFN) messenger RNA (mRNA) in fine needle aspiration biopsy (FNAB) by means of reverse transcription-polymerase chain reaction (RT-PCR). "

05/01/1997 - "This study sought to determine the value of oncofetal fibronectin as predictor of preterm delivery in patients presenting with preterm labor. "
11/01/1996 - "Alterations in levels of oncofetal fibronectin occur in preterm labor, postterm pregnancy, and pregnancy-induced hypertension. "
03/01/1999 - "Two biochemical tests, one for oncofetal fibronectin (fFN) and the other for estriol found in maternal saliva (SalEst) have been developed to improve the ability to predict preterm labor and birth. "
11/01/1996 - "Oncofetal fibronectin may become a clinical indicator or predictor of true labor, preterm labor, or some complications of pregnancy. "
01/01/2020 - "The following data were collected: gestational age, the presence of histologic chorioamnionitis, time from the diagnosis of threatened premature labor to delivery, oncofetal fibronectin (onfFN) levels, C-reactive protein peak value levels, cervical length at the time of onset of threatened premature labor and types of neonatal complications. "

01/01/2017 - "EDB-FN, one of the subtypes of oncofetal fibronectin, is involved in tumor epithelial-to-mesenchymal transition (EMT), which is implicated in drug resistance and metastasis. "
06/15/1995 - "Expression of oncofetal fibronectin (oncFN) and normal fibronectin (norFN) in colorectal cancer specimens was examined to investigate the correlation between fibronectin localization and histologic grade, liver metastasis, and prognosis. "
02/01/2012 - "The study was aimed at determining the vascular expression of oncofetal fibronectin (oncfFn) and tenascin-C (oncfTn-C) isoforms in renal cell carcinoma (RCC) and its metastases which are well-known targets for antibody-based pharmacodelivery. "